The current board is composed of nine members and is led by founder and chair of the board of directors, Mariam S. Darsot.
The appointments come as Nexus works to expand its offerings to include new products as well as Nexus Pharma Services.
Lee is the Founder and Managing Member of Sagent Group and brings over twenty years of experience investing in and advising companies in the life sciences and technology, media, and telecommunications industries.
Prior to the founding of Sagent Group, he served as the founder and portfolio manager of Oaktree's USD 6bn Strategic Credit strategy as well as serving as CEO and CIO of the organization's three business development companies.
Lee also brings experience from his work in TMT investment banking at UBS in Los Angeles, fixed income at Lehman Brothers, management consulting at Katzenbach Partners (Booz & Co.) and economic research at the Urban Institute.
He holds a B.A. degree in economics from Swarthmore College and a master's degree from Harvard University.
Warmuth was most recently an Operating Partner at EW Healthcare Partners from 2018 to 2022.
Prior to EW Healthcare Partners, Warmuth was at Abbott Laboratories, where he led the Established Pharmaceuticals division which soon became one of the top ten largest generics companies across the globe and covered several therapeutic areas including gastroenterology, women's health, cardiovascular, and metabolic disorders.
His work at Abbott reflects a strong track record of success in driving operational excellence and growth through mergers and acquisitions. He holds a B.A. degree in Business Administration from the University of Wisconsin-Whitewater and a master's degree from Northwestern University.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development